CAR-T cell therapy for active residual large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new CAR-T cell treatment for people with large B-cell lymphoma who still have active cancer cells in their blood after finishing standard chemotherapy. It aims to see if the treatment can eliminate these remaining cancer cells and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of large B-cell lymphoma that has not responded completely to standard chemotherapy.
- You have completed your first round of standard chemotherapy including drugs like rituximab and an anthracycline.
- You have detectable cancer DNA in your blood after finishing chemotherapy.
- You are at least 18 years old and in reasonably good health as determined by your doctor.
- You have not had a prior CAR-T cell treatment or allogeneic transplant.
- You are willing to use contraception if needed and can follow study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special cell therapy called CAR-T that targets CD19 on lymphoma cells. It is for people with aggressive large B-cell lymphoma that has not responded to standard treatments or has come back after treatment.
This trial tests a CAR-T cell treatment made to target CD19 on lymphoma cells (PL001). It’s for people whose B-cell lymphoma has come back or not responded to standard treatments, aiming to shrink the cancer and help control the disease.
This trial tests CY-219, a type of cell therapy that trains your immune cells to fight B-cell lymphoma that has come back or stopped responding to standard treatments. The study evaluates whether this approach is safe and effective for patients like you.
This trial tests a combination treatment: a stem cell transplant followed by CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. It is for those with high-risk features like large tumors or certain genetic changes.
This trial tests an experimental CAR-T cell therapy—a treatment that uses your own immune cells modified to fight cancer—for B-cell lymphoma that has returned or stopped responding to previous treatments. Researchers are studying how well this therapy works in real-world practice.
This trial tests a combination of two treatments: a CAR-T cell therapy (relmacabtagene autoleucel) and an immunotherapy drug (sintilimab) for people with certain types of B-cell lymphoma that have come back or stopped responding to other treatments. The goal is to see if this combination can help control the cancer.
Hear when a new Large-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.